Skip to content

Improving Physical Health in Patients With Psychiatric Disorders in General Practice (SOFIA)

A Cluster Randomized, Pilot Trial of Coordinated, Co-produced Care to Reduce Excess Mortality and Improve Quality of Life in Patients With Severe Mental Illness in General Practice Setting

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04618250
Acronym
SOFIA
Enrollment
76
Registered
2020-11-05
Start date
2020-11-06
Completion date
2021-09-30
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Psychiatric Disorder, Schizophrenia, Severe Depression

Brief summary

People with a severe mental illness (SMI) have an increased risk for premature mortality, predominantly due somatic health conditions. Evidence indicates that prevention and improved treatment of somatic conditions in patients with SMI could reduce this excess mortality. This paper reports a protocol designed to evaluate the feasibility and acceptability of a coordinated co-produced care programme (SOFIA model) in the general practice setting to reduce mortality and improve quality of life in patients with severe mental illness. The primary outcomes are description of study feasibility (recruitment and retention) and acceptability. The SOFIA trial is designed as cluster randomized controlled trial targeting general practices in two regions in Denmark. 12 practices will each recruit 15 community-dwelling patients aged 18 and older with severe mental illness (SMI). Practices will be randomized in a ratio 2:1 to deliver a coordinated care program or care-as-usual during a 6 month period. An online randomized algorithm is used to perform randomization. The coordinated care program comprises enhanced educational training of general practitioners and their clinical staff, and prolonged consultations focusing on individual needs and preferences of the patient with SMI. Assessments are administered at baseline, and at end of study period. If delivery of the intervention in the general practice setting proves feasible, a future definitive trial to determine the effectiveness of the intervention in reducing mortality and improving quality of life in patients with SMI can take place.

Interventions

OTHERSOFIA model

A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan

Sponsors

University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Registered at a general practice situated in the Danish Capital Region or the Region of Zealand; * Registered at general practice with International Classification of Primary Care version 2 (ICPC-2) diagnostic code p72 (psychotic disorders); * Registered at general practice with ICPC-2 diagnostic code p73 (bipolar mood disorders); * Prescription of Lithium (Anatomical Therapeutic Chemical (ATC): N05AN); * Registered at general practice with ICPC-2 diagnostic code p76 AND (Prescription of Lamotrigine (N03A09) OR Carbamazepine (N03AF01) OR Valproic Acid (N03AG01)); * Registered at general practice with ICPC-2 diagnostic code p76 (unipolar depressive disorders) AND (Prescription of tricyclic antidepressants (N06AA) AND/OR venlafaxine (N06AX16) AND/OR duloxetine (N06AX21) AND/OR Monoamine Oxidase A Inhibitor (MAOi) (N06AG) AND/OR non-selective MAOi (N06AF)).

Exclusion criteria

* Subjected to any type of legal measure as stipulated in the Danish Mental Health Law; * Registered with a dementia diagnosis ICPC-2 p70 (dementia); * Receiving end-of-life care; * Non-Danish speakers; * Assumed by the patient's general practitioner to have an overall functional level that is too low for meaningful participation in trial.

Design outcomes

Primary

MeasureTime frameDescription
Hospitalizations6 months after randomizationNumber of all-cause in- and outpatient hospitalizations of participants during the 6 months trial period.
Effectiveness of the collecting Multimorbidity Questionnaires6 months after randomizationProportion of returned and completed Multimorbidity Questionnaires.
Effectiveness of the collecting EQ5D-5L questionnaires6 months after randomizationProportion of returned and completed EQ5D-5L questionnaire.
Mortality6 months after randomizationNumber of all-cause deaths of participants during the 6 month trial period.
Effectiveness of the design in terms of recruitment of practices and patients6 months after randomizationProportion of contacted general practices, which agree to participate in the study and the eligibility and consent rate of patients.
Acceptability of the intervention for patients and general practitioners, staff and patients.Entire study period (6 months)Qualitative semi-structured interviews with patients and general practitioners, staff and patients.
Retention of patients during the study6 months after randomizationProportion of recruited patients in the intervention group who attend the first consultation.
Acceptability of REDcap software for general practitionersEntire study period (6 months)Qualitative semi-structured interviews with general practitioners.

Secondary

MeasureTime frameDescription
Multimorbidity Questionnaires (MMQ) scores3 times during study period (at baseline, before prolonged consultation and 6 months after randomizationScores on Multimorbidity Questionnaire

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026